|
|
晚期卵巢癌中西医同步管理思路探析
|
Abstract:
卵巢癌死亡率居妇科恶性肿瘤之首，目前卵巢癌的西医治疗以手术 + 化疗 + 维持治疗的综合治疗模式为标准，预后逐渐改善，但是卵巢癌患者在综合治疗阶段，多数会出现与治疗相关的不良副反应及诸多并发症，导致患者自身身体耐受性下降，不能实时跟进后续治疗。近年来中医药治疗卵巢癌的优势日益凸显，辅以中药可促进术后快速恢复，解除相应并发症，使卵巢癌患者按制定的治疗模式实时完成后续治疗，延缓复发。本文以目前的西医标准综合治疗模式：手术 + 化疗 + 维持治疗为主，辅以中药，分阶段探讨中西医同步管理卵巢癌，为后续中西医结合治疗卵巢癌提供新思路。
Ovarian cancer has the highest mortality among gynecological malignancies. The current standard Western medicine treatment is surgery + chemotherapy +maintenance treatment, and the prognosis is improving. But patients often have treatment-related side effects and complications, reducing their tolerance and hindering follow-up treatment. In recent years, the advantages of traditional Chinese medicine in treating ovarian cancer have emerged. With TCM supplementation, it can promote postoperative recovery, relieve complications, enable patients to complete subsequent treatment on time, and delay recurrence. This article focuses on the Western medicine comprehensive treatment model (surgery + chemotherapy + maintenance treatment) supplemented with TCM, exploring the synchronous management of ovarian cancer in stages to provide new ideas for the integrated treatment.
| [1] | Morgan, R.D., Banerjee, S., Hall, M., Clamp, A.R., Zhou, C., Hasan, J., et al. (2020) Pazopanib and Fosbretabulin in Recurrent Ovarian Cancer (PAZOFOS): A Multi-Centre, Phase 1b and Open-Label, Randomised Phase 2 Trial. Gynecologic Oncology, 156, 545-551. https://doi.org/10.1016/j.ygyno.2020.01.005 |
| [2] | Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660 |
| [3] | Cabasag, C.J., Fagan, P.J., Ferlay, J., Vignat, J., Laversanne, M., Liu, L., et al. (2022) Ovarian Cancer Today and Tomorrow: A Global Assessment by World Region and Human Development Index Using GLOBOCAN 2020. International Journal of Cancer, 151, 1535-1541. https://doi.org/10.1002/ijc.34002 |
| [4] | 宣跃廷, 程红. 国医大师徐经世从肝论治卵巢癌术后化疗期[J]. 中医药临床杂志, 2020, 32(1): 38-41. |
| [5] | 王瑞杰, 齐聪. 齐聪教授治疗卵巢癌经验[J]. 四川中医, 2010, 28(2): 1-2. |
| [6] | 刘华, 桂联花. 小承气汤对卵巢癌术后胃肠功能影响的临床研究[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(92): 172-173. |
| [7] | 田叶红, 邱晓伟, 姜欣, 等. 从以毒攻毒治癌理念探析壁虎的临床运用[J]. 环球中医药, 2020, 13(6): 1039-1041. |
| [8] | 王照东方, 张静, 周佳琳, 等. 李佩文教授辨治化疗性脱 发经验探析[J]. 中日友好医院学报, 2021, 35(2): 121, 126. |
| [9] | 黄宏, 沈敏鹤, 阮善明, 等. 吴良村治疗卵巢癌经验[J]. 中医杂志, 2017, 58(9): 737-740. |
| [10] | 许秀灵. 参芪扶正注射液联合益气汤在卵巢癌治疗中增敏减毒临床研究[J]. 临床医药文献杂志(连续型电子期刊), 2017, 4(A3): 20376, 20378. |
| [11] | 中国抗癌协会妇科肿瘤专业委员会. 卵巢恶性肿瘤诊断与治疗指南(2021年版) [J]. 中国癌症杂志, 2021, 31(6): 490-500. |
| [12] | 吴晓晴, 陈秋叶, 卢雯平. 卵巢上皮性癌中西医维持治疗的研究进展[J]. 医学综述, 2020, 26(19): 3806-3813. |
| [13] | 杨美清, 刘海涛, 杨蕴, 等. 基于数据挖掘的田建辉治疗妇科癌、用药规律研究[J]. 上海中医药杂志, 2020, 54(5): 61-65. |
| [14] | 韩凤娟, 沈影. 试论中医体质与卵巢癌发病的微观因子中介机制[J]. 上海中医药杂志, 2015, 49(12): 8-10. |
